35 Without this stimulus, especially during a calorie deficit potentially exacerbated by GLP-1 effects, the body may be less efficient at utilizing dietary protein for muscle maintenance, leading to greater lean mass loss
Eli Lilly and Company Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes
Before starting any patient on a GLP-1 medication, I always explain how important it is to maintain their protein intake and keep up with resistance training
Patients no longer want temporary fixes
Looking for GLP-1 medications to support your weight loss journey, but want a more affordable option
Lilly's next-gen Triple G (GLP-1/GIP/glucagon) agonist (Phase 1b, Phase 2): started recruiting for a Phase 3 trial this year approvals are expected by 2026